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ABSTRACT 
The  aim  of  this  study  was  to  develop  a  single  combined  once daily  sustained  release 
microencapsulated  dosage  form  of  Allopurinol  and  Nimesulide  using  Ethyl  cellulose  as  release 
controlling factor and to evaluate drug release parameters as per various release kinetic models. In 
order to achieve required sustained release profile, microparticles were prepared using coacervation 
thermal change technique. The formulated microparticles were also characterized by physical and 
chemical parameters and results were found in acceptable limits. Different dissolution models were 
applied to drug release data in order to evaluate release mechanisms and kinetics. The drug release 
data fit well to the Higuchi expression. Drug release mechanism was found as a complex anomalous 
one. 
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INTRODUCTION 
Chronic diseases are increasing drastically now a days. This situation requires the use 
of a number of drugs and for a longer period simultaneously, which causes an increase in 
patient non compliance. This problem proves to be serious for drugs with short biological half 
lives because they must be taken more frequently. To solve such problems one method is to 
design a dosage form which releases drug gradually. In this regard, microencapsulation has 
been  used  as  one  of  the  techniques  to  design  a  formulation  for  delivering  the  drug  in  a 
controlled manner 
1. Microencapsulation ia a technique that involves the coating of some 
active substance by some suitable polymer resulting in fine free flowing tiny particles 
2. 
Allopurinol  (1H pyrazolo  [3,4 d]pyrimidin 4 ol)  is  a  commonly  used  drug  in  the 
treatment of chronic gout or hyperuricaemia associated with leukaemia, radiotherapy, anti 
neoplastic agents and treatment with diuretics conditions 
1. Allopurinol is a structural isomer 
of hypoxanthine (a naturally occurring purine in the body) and acts to inhibit xanthine oxidase 
In the presence of xanthine oxidase, Allopurinol will be converted to Allopurinolxanthine, MURTAZA G et al. Development of a Single Combined Microencapsulated …  106 
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after that the formation of uric acid from xanthine and hypoxanthine will be inhibited. This 
enzyme is responsible for the successive oxidation of hypoxanthine and xanthine resulting in 
the production of uric acid, the product of human purine metabolism 
2 4. Direct use of this 
drug can have several side effects on the skin or digestive system and which appear in the 
form of fevering, shivering and vomiting 
5. The microencapsulation of this drug can reduce 
any side effects largely.  
Nimesulide  is  described  chemically  as  N (4 nitro 2 phenoxyphenyl)  methane 
sulphonamide classified as a nonsteroidal anti inflammatory drug (NSAID). It is a unique 
nonsteroidal  anti inflammatory  (NSAID)  agent  having  specific  affinity  to  inhibit 
cyclooxygenase 2 enzyme 
6. It is effective in reducing pain associated with osteoarthritis, 
rheumatoid,  and  other  degenerative  joints  disorders,  low  back  pain,  dysmenorrhoea, 
gynaecological  condition,  thrombophlebitis,  dental  pain  and  inflammations  etc. 
7,8.  It  a 
slightly acidic and because of this character it causes G.I irritation, so microencapsulation 
technique can be used to prevent GI irritation.  
These two drugs should be prescribed in combination in gout as an uricosoric agent 
(Allopurinol)  and  an  NSAID  (Nimesulide).  Due  to  above  mentioned  side  effects  of 
Allopurinol and Nimesulide, they were formulated into a single stable oral dosage form to 
increase  the  patient  compliance.  Both  drugs  were  microencapsulated  separately  into 
ethylcellulose, evaluated for any chemical interaction, determined their entrapment efficiency 
of specified amount of microparticles and filled in a hard gelatin capsule shell of appropriate 
size after mixing drug release study. 
1. MATERIAL AND METHODS 
1.1 Material 
Allopurinol active as a kind gift GSK Pvt. (Ltd.) Karachi Pakistan, Nimesulide active 
as a gift from Pharm Evo Pharma Pvt. (Ltd) Karachi, Pakistan, Ethyl cellulose from Sigma 
(USA). The chemicals such as cyclohexane, liquid paraffin (heavy and light) and n hexane of 
analytical grade supplied by Merck (Germany). 
1.2 Preparation of microparticles 
Coacervation thermal change technique was selected for this study keeping in mind 
the  physico chemical  properties  of  both  drugs  e.g.  melting  points  of  Allopurinol  and 
nimesulide are 300 °C and 145 °C, respectively. A weighed amount (1 g) of ethyl cellulose 22 
cp as a polymer was dissolved in specific amount of cyclohexane (30 ml) as a solvent by 
heating to 70 80 °C with vigorous stirring with the help of magnetic stirrer at 150 RPM. In 
this  solution,  weighed  amount  (1  g)  of  drug  was  dispersed.  Vigorous  stirring  and  high 
temperature  was  maintained  throughout  the  process.  The  temperature  was  then  slowly 
reduced using cold water bath to induce phase separation. The product obtained was washed 
thrice with n hexane (100 ml) at room temperature, air dried following oven drying at 45 °C MURTAZA G et al. Development of a Single Combined Microencapsulated …  107 
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and passed through sieve no. 80 to separate individual microcapsules 
9. After determination of 
entrapment efficiency, they were filled in to capsules shell of appropriate size (000) for in 
vitro  release  study  so  that  each  capsule  should  contain  300  mg  Allopurinol  and  200  mg 
Nimesulide. 
1.3 In vitro drug release of microparticles 
In vitro drug release of various microparticles filled capsules was determined using 
automatic apparatus I USP (Rotating basket, Pharma Test, Germany) in 900 ml of phosphate 
buffer (pH 6.8). 5 ml of sample was collected at 0; 0.25; 0.5; 1.0; 1.5; 2.0; 3.0; 4.0; 6.0; 8.0 
and 10 hours with an automated fraction collector after filtering through 10  m Sinter filters. 
All samples were analyzed as such at 404 nm for Nimesulide and at 250 nm for Allopurinol 
using a UV spectrophotometer (Shimadzu 1601, Japan). Percentage drug release at different 
sampling intervals was calculated. 
1.4 Determination of drug loading, encapsulation efficiency and microparticles yield 
For the determination of amount of Allopurinol in the microcapsules, a known amount 
of microcapsules is taken and polymer solvent (Methylene chloride) is added. In this way, the 
wall polymer was dissolved and drug sediment. The solution was filtered, what is left on the 
filter paper was separated, and again polymer solvent was added. This is done several times 
and what is left on the filter paper is the amount of the drug. It is weighed anti the drug for a 
known amount of microcapsule material is calculated. 
Average  Nimesulide  content  was  measured  by  extracting  a  sample  of  20  mg  of 
microparticles using methanol. After filtration and appropriate dilution, the concentration was 
determined  using  the  spectrophotometer  (Shamidzo Japan  1601).  Percentage  drug  loading 
was calculated using the following equation: 
Loading (%) = (Weight of drug/Weight of microparticle) x 100 
The encapsulation efficiency was determined by the following equation: 
Encapsulation efficiency (%) = (Calculated drug content/Theoretical drug content) x 100 
The yield % of the produced microparticles was calculated for each batch by dividing the 
weight of microparticles (M) by the total expected weight of drug and polymer (M0): 
Yield % = (M/M0) x 100 
Each determination was performed in triplicate 
9. 
1.5 Particle size analysis 
Particle size was determined by sieve method. The mean particle size was calculated MURTAZA G et al. Development of a Single Combined Microencapsulated …  108 
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after sieving as follows 
10; 
dave = ∑ nd / ∑ n 
Where dave is the arithmetic mean diameter of microparticles, ‘n’ is percentage weight 
fraction retained on smaller sieve and ‘d’ is the arithmetic mean size of sieve opening. 
1.6 Flow properties 
Angle  of  repose  of  different  formulations  was  measured  according  to  the  fixed  funnel 
standing cone method and was given by 
9: 
θ = tan
 1 hr 
 1 
Where θ is the repose angle, r is the radius and h is the height. 
Bulk  density  was  measured  by  tapping  method 
9.  Kawakita  equation  was  used  to 
calculate the packing rate (b) according to the following equation 
9: 
n/c =(1/ab) + (n/ab) 
C = (Vo Vn)/ Vo 
Where a and b are constants representing the proportion of consolidation at the closest 
packing attained and packing rate, respectively, n is the number of taps, Vo and Vn are the 
powder bed volumes at initial and tapped state, respectively. 
Compressibility index (Ci) or carr’s index values of microparticles was computed according 
to the following equation 
9: 
Carr% = [(tapped density   fluff density) / tapped density] x 100 
Hausner ratios of microparticles were determined by comparing the tapped density to the fluff 
density using the equation 
9. 
Hausner’s ratio = tapped density / fluff density   
1.7 Kinetic treatment of release data 
The  obtained  dissolution  data  were  fitted  to  zero  order,  first  order,  Higuchi, 
Korsmeyer Peppas, and Hixson Crowell to determine the mechanism of drugs release from 
the prepared microparticles 
9. 
1.8 X-ray diffraction studies 
The physical nature of the drug substances in microparticles was determined using the MURTAZA G et al. Development of a Single Combined Microencapsulated …  109 
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X ray diffraction method (Philips PW 1830). Powdered samples of Nimesulide, Allopurinol, 
ethylcellulose and their microparticles were examined for comparison. 
1.9 FTIR spectroscopy studies 
FTIR spectra of the drug substances, polymer, and microparticles were obtained using 
a (model FTIR 8400 S Shimadzu, Japan) FTIR spectrophotometer. 
2 RESULTS AND DISCUSSION 
The coacervation thermal change technique was applied to prepare Nimesulide and 
Allopurinol microparticles. Cyclohexane (at high temperature) was used as a solvent for ethyl 
cellulose,  whereas  Nimesulide  and  Allopurinol  are  cyclohexane  insoluble  drugs. 
Ethylcellulose  was  used  as  a  wall forming  material  because  of  its  safety,  stability, 
hydrophobicity and compact film forming nature among water insoluble polymers 
11. 
The microparticles of Allopurinol were white, free flowing and spherical whereas the 
microparticles of Allopurinol were light yellow, free flowing and spherical as observed under 
scanning electron microscope (Figure 1). The mean particle size varied between 126 137  m 
for  different  formulations  of  Allopurinol Nimesulide Ethylcellulose  microparticles.  The 
entrapment efficiency (Table 1) of the microparticles was 93% and 94% for Allopurinol and 
Nimesulide, respectively. The rest of micromeritic characteristics are given in table 1. Weight 
variation of capsules was with in the limits. 
Table 1: Characterization of microparticles 
Formulations  Allopurinol  Nimesulide 
Bulk density (g/ml)  0.173  0.263 
Taped density (g/ml)  0.203  0.302 
Hausner’s ratio  1.176  1.15 
Compressibility index (%)  15  13 
Angle of repose  22.47
o  21.67
o 
Packing rate (C)  0.15  0.13 
Yield (%)  96  96 
Entrapment efficiency (%)  93  94 
Particle size (µm)  137  126 
 
 
Figure 1: Scanning electron microscope of microparticles 
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2.1 Drug release kinetics 
As shown in Figure 2, 3 & 4, various plots are drawn in accordance with various 
release kinetic models, are giving linear relationship. In Zero order plot (Figure 2), the R
2 
value is 0.9405, 0.983  and first order (Figure  3)  giving 0.5134  and 0.5913 (Table 2)  for 
Allopurinol and Nimesulide  respectively describing the relationship between drug release 
rate and concentration of drug and we can see it that drug release is independent of drug 
concentration. The best fitting was found in Higuchi’s model (Table 2) (R
2 = 0.9889, R
2 = 
9672  for  Allopurinol  and  Nimesulide,  respectively)  indicating  the  release  of  drug  from 
microparticles as a square root of time dependent process based on Fickian diffusion. 
Figure 2: Dissolution profile of Allopurinol and Nimesulide in microparticles 
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Figure 3: Plots of different kinetic models for allopurinol 
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Figure 4: Plots of different kinetic models for nimesulide 
 
 
 
 
The dissolution release data was also plotted according to Hixson Crowell cube root 
model  (Table  2).  Applicability  of  data  (R
2  =  0.9872,  R
2  =  0.9701  for  Allopurinol  and 
Nimesulide, respectively) shows a change in surface area and diameter of microparticles with 
the progressive dissolution of as a function of time. 
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Table 2: Goodness of Fit (using R
2) for mathematical models used for determining drug release rate 
 
Microparticles  Models  Parameters 
Allopurinol  Nimesulide 
Y equation  8.980x + 14.335  8.345x + 7.8084 
Zero Order 
R
2  0.9405  0.983 
Y equation  0.288x + 2.388  0.299x + 2.129 
First Order 
R
2  0.5134  0.5913 
Y equation  31.361x   5.663  28.193x   9.1542 
Higuchi 
R
2  0.9889  0.9672 
Y equation   0.272x + 4.572   0.219x + 4.644 
Hixson-Crowell 
R
2  0.9872  0.9701 
Y equation  0.557x + 3.242  0.681x + 2.843 
r
2  0.9839  0.9866  Korsmeyer-peppa 
n 
(release exponent)  0.55  0.68 
2.2 Mechanism of drug release 
By incorporating the first 60% of dissolution release data, mechanism of release can 
be  indicated  according  to  Korsmeyer  where  “n”  is  the  release  exponent,  indicative  of 
mechanism of drug release. Fickian diffusional release and a case II relaxational release are 
the  limits  of  this  phenomenon.  Fickian  diffusional  release  occurs  due  to  the  molecular 
diffusion  of  the  drug  because  of  chemical  potential  gradient.  Case II  relaxational  release 
occurs due to stresses and state transition in hydrophilic glassy polymers which swell in water 
or biological fluids. This term also includes polymer disentanglement and erosion 
12.  The 
value  of  the  release  exponent  ‘n’  in  Allopurinol  and  Nimesulide  sustained  release 
microparticles  obtained  as  0.55  and  0.68  (for  Allopurinol  and  Nimesulide    respectively) 
shows anomalous or non Fickian diffusion. 
And from the XRD and FTIR studies (Figure 5 and 6) it is clear that the slight changes 
may be due to polymorphism of the drug and not due to strong interaction between the drug 
and polymer which confirms the stability of formulation.  
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Figure 5. XRD of A (active nimesulide), B (active allopurinol), C (ethylcellulose), D (microparticles 
of nimesulide), E (microparticles of allopurinol). 
 
Figure 6. FTIR of A (active nimesulide), B (active allopurinol), C (ethylcellulose), D (microparticles 
of nimesulide), E (microparticles of allopurinol). MURTAZA G et al. Development of a Single Combined Microencapsulated …  115 
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3. CONCLUSION 
Allopurinol Nimesulide sustained release microencapsulated single dosage form was 
prepared successfully using ethylcellulose as polymer to retard release and achieve required 
dissolution profile. Drug release kinetics of this formulation correspond best to Higuchi’s 
model and drug release mechanism as per “n” value of Korsmeyer & Peppas (Power law) was 
found to be anomalous diffusion. 
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